Integrated Liquid Biopsy Profiling to Accelerate RAS Clinical Drug Development
- Genomic ultra-deep profiling using a blood-informed minimal residual disease (MRD) approach to support RAS-targeted clinical trials and enable data-driven go/no-go decision-making
- Epigenomic methylation profiling for enhanced detection of therapy response dynamics and resistance mechanisms
- Tissue and blood-based RNA profiling to advance next-generation RAS drug development through transcriptomic insights